APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chagas Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Chagas Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025194 pages

Choose your research edition.

Industry ResearchChagas Disease Treatment Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Chagas Disease Treatment Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Chagas Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chagas Disease Treatment Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Chagas Disease Treatment Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Chagas Disease Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Chagas Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chagas Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chagas Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Chagas Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Chagas Disease Treatment include Daiichi Sankyo Company Ltd, Eisai Co Ltd, ELEA SACIF Laboratory, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Grupo Praxis Pharmaceutical SA, KaloBios Pharmaceuticals, Inc, Kancera AB and Laboratorio Elea Phoenix SA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chagas Disease Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chagas Disease Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chagas Disease Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chagas Disease Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Chagas Disease Treatment Segment by Company

Daiichi Sankyo Company Ltd

Eisai Co Ltd

ELEA SACIF Laboratory

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Grupo Praxis Pharmaceutical SA

KaloBios Pharmaceuticals, Inc

Kancera AB

Laboratorio Elea Phoenix SA

Laboratorio Farmaceutico De Pernambuco

Maprimed S.A

Nortec Quimica SA

Novartis AG

Oblita Therapeutics BVBA

Sanofi Aventis

AstraZeneca

Bayer AG

Johnson & Johnson

Chagas Disease Treatment Segment by Type

Benznidazole

Nifurtimox

Chagas Disease Treatment Segment by Application

Hospitals

Online Pharmacies

Retail Pharmacies

Chagas Disease Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chagas Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chagas Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chagas Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chagas Disease Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chagas Disease Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Chagas Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Chagas Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Chagas Disease Treatment Industry Trends Table 2. Chagas Disease Treatment Industry Drivers Table 3. Chagas Disease Treatment Industry Opportunities and Challenges Table 4. Chagas Disease Treatment Industry Restraints Table 5. Global Chagas Disease Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Chagas Disease Treatment Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Chagas Disease Treatment Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Chagas Disease Treatment Sales Market Share by Manufacturers Table 9. Global Chagas Disease Treatment Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Chagas Disease Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Chagas Disease Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Chagas Disease Treatment Manufacturers, Product Type & Application Table 13. Global Chagas Disease Treatment Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Chagas Disease Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Benznidazole Table 17. Major Manufacturers of Nifurtimox Table 18. Global Chagas Disease Treatment Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Chagas Disease Treatment Sales by Type (2021-2026) & (k units) Table 20. Global Chagas Disease Treatment Sales by Type (2027-2032) & (k units) Table 21. Global Chagas Disease Treatment Sales Market Share by Type (2021-2026) Table 22. Global Chagas Disease Treatment Sales Market Share by Type (2027-2032) Table 23. Global Chagas Disease Treatment Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Chagas Disease Treatment Revenue by Type (2021-2026) & (k units) Table 25. Global Chagas Disease Treatment Revenue by Type (2027-2032) & (k units) Table 26. Global Chagas Disease Treatment Revenue Market Share by Type (2021-2026) Table 27. Global Chagas Disease Treatment Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospitals Table 29. Major Manufacturers of Online Pharmacies Table 30. Major Manufacturers of Retail Pharmacies Table 31. Global Chagas Disease Treatment Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Chagas Disease Treatment Sales by Application (2021-2026) & (k units) Table 33. Global Chagas Disease Treatment Sales by Application (2027-2032) & (k units) Table 34. Global Chagas Disease Treatment Sales Market Share by Application (2021-2026) Table 35. Global Chagas Disease Treatment Sales Market Share by Application (2027-2032) Table 36. Global Chagas Disease Treatment Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Chagas Disease Treatment Revenue by Application (2021-2026) & (k units) Table 38. Global Chagas Disease Treatment Revenue by Application (2027-2032) & (k units) Table 39. Global Chagas Disease Treatment Revenue Market Share by Application (2021-2026) Table 40. Global Chagas Disease Treatment Revenue Market Share by Application (2027-2032) Table 41. Global Chagas Disease Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Chagas Disease Treatment Sales by Region (2021-2026) & (k units) Table 43. Global Chagas Disease Treatment Sales Market Share by Region (2021-2026) Table 44. Global Chagas Disease Treatment Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Chagas Disease Treatment Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Chagas Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Chagas Disease Treatment Sales by Country (2021-2026) & (k units) Table 48. North America Chagas Disease Treatment Sales by Country (2027-2032) & (k units) Table 49. Europe Chagas Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Chagas Disease Treatment Sales by Country (2021-2026) & (k units) Table 51. Europe Chagas Disease Treatment Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Chagas Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Chagas Disease Treatment Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Chagas Disease Treatment Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Chagas Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Chagas Disease Treatment Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Chagas Disease Treatment Sales by Country (2027-2032) & (k units) Table 58. Global Chagas Disease Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Chagas Disease Treatment Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Chagas Disease Treatment Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Chagas Disease Treatment Revenue Market Share by Region (2021-2026) Table 62. Global Chagas Disease Treatment Revenue Market Share by Region (2027-2032) Table 63. Daiichi Sankyo Company Ltd Company Information Table 64. Daiichi Sankyo Company Ltd Business Overview Table 65. Daiichi Sankyo Company Ltd Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Daiichi Sankyo Company Ltd Chagas Disease Treatment Product Portfolio Table 67. Daiichi Sankyo Company Ltd Recent Development Table 68. Eisai Co Ltd Company Information Table 69. Eisai Co Ltd Business Overview Table 70. Eisai Co Ltd Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Eisai Co Ltd Chagas Disease Treatment Product Portfolio Table 72. Eisai Co Ltd Recent Development Table 73. ELEA SACIF Laboratory Company Information Table 74. ELEA SACIF Laboratory Business Overview Table 75. ELEA SACIF Laboratory Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. ELEA SACIF Laboratory Chagas Disease Treatment Product Portfolio Table 77. ELEA SACIF Laboratory Recent Development Table 78. F. Hoffmann-La Roche Ltd. Company Information Table 79. F. Hoffmann-La Roche Ltd. Business Overview Table 80. F. Hoffmann-La Roche Ltd. Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. F. Hoffmann-La Roche Ltd. Chagas Disease Treatment Product Portfolio Table 82. F. Hoffmann-La Roche Ltd. Recent Development Table 83. GlaxoSmithKline Plc Company Information Table 84. GlaxoSmithKline Plc Business Overview Table 85. GlaxoSmithKline Plc Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. GlaxoSmithKline Plc Chagas Disease Treatment Product Portfolio Table 87. GlaxoSmithKline Plc Recent Development Table 88. Grupo Praxis Pharmaceutical SA Company Information Table 89. Grupo Praxis Pharmaceutical SA Business Overview Table 90. Grupo Praxis Pharmaceutical SA Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Grupo Praxis Pharmaceutical SA Chagas Disease Treatment Product Portfolio Table 92. Grupo Praxis Pharmaceutical SA Recent Development Table 93. KaloBios Pharmaceuticals, Inc Company Information Table 94. KaloBios Pharmaceuticals, Inc Business Overview Table 95. KaloBios Pharmaceuticals, Inc Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. KaloBios Pharmaceuticals, Inc Chagas Disease Treatment Product Portfolio Table 97. KaloBios Pharmaceuticals, Inc Recent Development Table 98. Kancera AB Company Information Table 99. Kancera AB Business Overview Table 100. Kancera AB Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Kancera AB Chagas Disease Treatment Product Portfolio Table 102. Kancera AB Recent Development Table 103. Laboratorio Elea Phoenix SA Company Information Table 104. Laboratorio Elea Phoenix SA Business Overview Table 105. Laboratorio Elea Phoenix SA Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Laboratorio Elea Phoenix SA Chagas Disease Treatment Product Portfolio Table 107. Laboratorio Elea Phoenix SA Recent Development Table 108. Laboratorio Farmaceutico De Pernambuco Company Information Table 109. Laboratorio Farmaceutico De Pernambuco Business Overview Table 110. Laboratorio Farmaceutico De Pernambuco Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Laboratorio Farmaceutico De Pernambuco Chagas Disease Treatment Product Portfolio Table 112. Laboratorio Farmaceutico De Pernambuco Recent Development Table 113. Maprimed S.A Company Information Table 114. Maprimed S.A Business Overview Table 115. Maprimed S.A Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Maprimed S.A Chagas Disease Treatment Product Portfolio Table 117. Maprimed S.A Recent Development Table 118. Nortec Quimica SA Company Information Table 119. Nortec Quimica SA Business Overview Table 120. Nortec Quimica SA Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Nortec Quimica SA Chagas Disease Treatment Product Portfolio Table 122. Nortec Quimica SA Recent Development Table 123. Novartis AG Company Information Table 124. Novartis AG Business Overview Table 125. Novartis AG Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Novartis AG Chagas Disease Treatment Product Portfolio Table 127. Novartis AG Recent Development Table 128. Oblita Therapeutics BVBA Company Information Table 129. Oblita Therapeutics BVBA Business Overview Table 130. Oblita Therapeutics BVBA Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Oblita Therapeutics BVBA Chagas Disease Treatment Product Portfolio Table 132. Oblita Therapeutics BVBA Recent Development Table 133. Sanofi Aventis Company Information Table 134. Sanofi Aventis Business Overview Table 135. Sanofi Aventis Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Sanofi Aventis Chagas Disease Treatment Product Portfolio Table 137. Sanofi Aventis Recent Development Table 138. AstraZeneca Company Information Table 139. AstraZeneca Business Overview Table 140. AstraZeneca Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. AstraZeneca Chagas Disease Treatment Product Portfolio Table 142. AstraZeneca Recent Development Table 143. Bayer AG Company Information Table 144. Bayer AG Business Overview Table 145. Bayer AG Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Bayer AG Chagas Disease Treatment Product Portfolio Table 147. Bayer AG Recent Development Table 148. Johnson & Johnson Company Information Table 149. Johnson & Johnson Business Overview Table 150. Johnson & Johnson Chagas Disease Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Johnson & Johnson Chagas Disease Treatment Product Portfolio Table 152. Johnson & Johnson Recent Development Table 153. Key Raw Materials Table 154. Raw Materials Key Suppliers Table 155. Chagas Disease Treatment Distributors List Table 156. Chagas Disease Treatment Customers List Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Chagas Disease Treatment Product Image Figure 2. Global Chagas Disease Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chagas Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Chagas Disease Treatment Sales (2021-2032) & (k units) Figure 5. Global Chagas Disease Treatment Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Chagas Disease Treatment Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Benznidazole Image Figure 9. Nifurtimox Image Figure 10. Global Chagas Disease Treatment Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Chagas Disease Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Chagas Disease Treatment Sales Market Share by Type (2021-2032) Figure 13. Global Chagas Disease Treatment Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Chagas Disease Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Chagas Disease Treatment Revenue Market Share by Type (2021-2032) Figure 16. Hospitals Image Figure 17. Online Pharmacies Image Figure 18. Retail Pharmacies Image Figure 19. Global Chagas Disease Treatment Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Chagas Disease Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Chagas Disease Treatment Sales Market Share by Application (2021-2032) Figure 22. Global Chagas Disease Treatment Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Chagas Disease Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Chagas Disease Treatment Revenue Market Share by Application (2021-2032) Figure 25. North America Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Chagas Disease Treatment Sales Market Share by Country (2021-2032) Figure 27. U.S. Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Chagas Disease Treatment Sales Market Share by Country (2021-2032) Figure 32. Germany Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Chagas Disease Treatment Sales Market Share by Country (2021-2032) Figure 39. China Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Chagas Disease Treatment Sales Market Share by Country (2021-2032) Figure 47. Brazil Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Chagas Disease Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Chagas Disease Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Chagas Disease Treatment Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Chagas Disease Treatment Revenue (2021-2032) & (US$ Million) Figure 58. North America Chagas Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Chagas Disease Treatment Revenue (2021-2032) & (US$ Million) Figure 60. Europe Chagas Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Chagas Disease Treatment Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Chagas Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Chagas Disease Treatment Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Chagas Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Chagas Disease Treatment Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Chagas Disease Treatment Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Benznidazole
  • Nifurtimox
Applications
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Daiichi Sankyo Company Ltd
  • Eisai Co Ltd
  • ELEA SACIF Laboratory
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Grupo Praxis Pharmaceutical SA
  • KaloBios Pharmaceuticals, Inc
  • Kancera AB
  • Laboratorio Elea Phoenix SA
  • Laboratorio Farmaceutico De Pernambuco
  • Maprimed S.A
  • Nortec Quimica SA
  • Novartis AG
  • Oblita Therapeutics BVBA
  • Sanofi Aventis
  • AstraZeneca
  • Bayer AG
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Chagas Disease Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Chagas Disease Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Chagas Disease Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Chagas Disease Treatment Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Chagas Disease Treatment Market Dynamics
  1. 2.1 Chagas Disease Treatment Industry Trends
  2. 2.2 Chagas Disease Treatment Industry Drivers
  3. 2.3 Chagas Disease Treatment Industry Opportunities and Challenges
  4. 2.4 Chagas Disease Treatment Industry Restraints
3 Chagas Disease Treatment Market by Manufacturers
  1. 3.1 Global Chagas Disease Treatment Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Chagas Disease Treatment Sales by Manufacturers (2021-2026)
  3. 3.3 Global Chagas Disease Treatment Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Chagas Disease Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chagas Disease Treatment Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Chagas Disease Treatment Manufacturers, Product Type & Application
  7. 3.7 Global Chagas Disease Treatment Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chagas Disease Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chagas Disease Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chagas Disease Treatment Tier 1, Tier 2, and Tier 3
4 Chagas Disease Treatment Market by Type
  1. 4.1 Chagas Disease Treatment Type Introduction
  2. 4.1.1 Benznidazole
  3. 4.1.2 Nifurtimox
  4. 4.2 Global Chagas Disease Treatment Sales by Type
  5. 4.2.1 Global Chagas Disease Treatment Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Chagas Disease Treatment Sales by Type (2021-2032)
  7. 4.2.3 Global Chagas Disease Treatment Sales Market Share by Type (2021-2032)
  8. 4.3 Global Chagas Disease Treatment Revenue by Type
  9. 4.3.1 Global Chagas Disease Treatment Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Chagas Disease Treatment Revenue by Type (2021-2032)
  11. 4.3.3 Global Chagas Disease Treatment Revenue Market Share by Type (2021-2032)
5 Chagas Disease Treatment Market by Application
  1. 5.1 Chagas Disease Treatment Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Chagas Disease Treatment Sales by Application
  6. 5.2.1 Global Chagas Disease Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chagas Disease Treatment Sales by Application (2021-2032)
  8. 5.2.3 Global Chagas Disease Treatment Sales Market Share by Application (2021-2032)
  9. 5.3 Global Chagas Disease Treatment Revenue by Application
  10. 5.3.1 Global Chagas Disease Treatment Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Chagas Disease Treatment Revenue by Application (2021-2032)
  12. 5.3.3 Global Chagas Disease Treatment Revenue Market Share by Application (2021-2032)
6 Global Chagas Disease Treatment Sales by Region
  1. 6.1 Global Chagas Disease Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chagas Disease Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Chagas Disease Treatment Sales by Region (2021-2026)
  4. 6.2.2 Global Chagas Disease Treatment Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Chagas Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Chagas Disease Treatment Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Chagas Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Chagas Disease Treatment Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Chagas Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Chagas Disease Treatment Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Chagas Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Chagas Disease Treatment Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Chagas Disease Treatment Revenue by Region
  1. 7.1 Global Chagas Disease Treatment Revenue by Region
  2. 7.1.1 Global Chagas Disease Treatment Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Chagas Disease Treatment Revenue by Region (2021-2026)
  4. 7.1.3 Global Chagas Disease Treatment Revenue by Region (2027-2032)
  5. 7.1.4 Global Chagas Disease Treatment Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Chagas Disease Treatment Revenue (2021-2032)
  8. 7.2.2 North America Chagas Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Chagas Disease Treatment Revenue (2021-2032)
  11. 7.3.2 Europe Chagas Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Chagas Disease Treatment Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Chagas Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Chagas Disease Treatment Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Chagas Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Daiichi Sankyo Company Ltd
  2. 8.1.1 Daiichi Sankyo Company Ltd Company Information
  3. 8.1.2 Daiichi Sankyo Company Ltd Business Overview
  4. 8.1.3 Daiichi Sankyo Company Ltd Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Daiichi Sankyo Company Ltd Chagas Disease Treatment Product Portfolio
  6. 8.1.5 Daiichi Sankyo Company Ltd Recent Developments
  7. 8.2 Eisai Co Ltd
  8. 8.2.1 Eisai Co Ltd Company Information
  9. 8.2.2 Eisai Co Ltd Business Overview
  10. 8.2.3 Eisai Co Ltd Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Co Ltd Chagas Disease Treatment Product Portfolio
  12. 8.2.5 Eisai Co Ltd Recent Developments
  13. 8.3 ELEA SACIF Laboratory
  14. 8.3.1 ELEA SACIF Laboratory Company Information
  15. 8.3.2 ELEA SACIF Laboratory Business Overview
  16. 8.3.3 ELEA SACIF Laboratory Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ELEA SACIF Laboratory Chagas Disease Treatment Product Portfolio
  18. 8.3.5 ELEA SACIF Laboratory Recent Developments
  19. 8.4 F. Hoffmann-La Roche Ltd.
  20. 8.4.1 F. Hoffmann-La Roche Ltd. Company Information
  21. 8.4.2 F. Hoffmann-La Roche Ltd. Business Overview
  22. 8.4.3 F. Hoffmann-La Roche Ltd. Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 F. Hoffmann-La Roche Ltd. Chagas Disease Treatment Product Portfolio
  24. 8.4.5 F. Hoffmann-La Roche Ltd. Recent Developments
  25. 8.5 GlaxoSmithKline Plc
  26. 8.5.1 GlaxoSmithKline Plc Company Information
  27. 8.5.2 GlaxoSmithKline Plc Business Overview
  28. 8.5.3 GlaxoSmithKline Plc Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Plc Chagas Disease Treatment Product Portfolio
  30. 8.5.5 GlaxoSmithKline Plc Recent Developments
  31. 8.6 Grupo Praxis Pharmaceutical SA
  32. 8.6.1 Grupo Praxis Pharmaceutical SA Company Information
  33. 8.6.2 Grupo Praxis Pharmaceutical SA Business Overview
  34. 8.6.3 Grupo Praxis Pharmaceutical SA Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Grupo Praxis Pharmaceutical SA Chagas Disease Treatment Product Portfolio
  36. 8.6.5 Grupo Praxis Pharmaceutical SA Recent Developments
  37. 8.7 KaloBios Pharmaceuticals, Inc
  38. 8.7.1 KaloBios Pharmaceuticals, Inc Company Information
  39. 8.7.2 KaloBios Pharmaceuticals, Inc Business Overview
  40. 8.7.3 KaloBios Pharmaceuticals, Inc Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 KaloBios Pharmaceuticals, Inc Chagas Disease Treatment Product Portfolio
  42. 8.7.5 KaloBios Pharmaceuticals, Inc Recent Developments
  43. 8.8 Kancera AB
  44. 8.8.1 Kancera AB Company Information
  45. 8.8.2 Kancera AB Business Overview
  46. 8.8.3 Kancera AB Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kancera AB Chagas Disease Treatment Product Portfolio
  48. 8.8.5 Kancera AB Recent Developments
  49. 8.9 Laboratorio Elea Phoenix SA
  50. 8.9.1 Laboratorio Elea Phoenix SA Company Information
  51. 8.9.2 Laboratorio Elea Phoenix SA Business Overview
  52. 8.9.3 Laboratorio Elea Phoenix SA Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Laboratorio Elea Phoenix SA Chagas Disease Treatment Product Portfolio
  54. 8.9.5 Laboratorio Elea Phoenix SA Recent Developments
  55. 8.10 Laboratorio Farmaceutico De Pernambuco
  56. 8.10.1 Laboratorio Farmaceutico De Pernambuco Company Information
  57. 8.10.2 Laboratorio Farmaceutico De Pernambuco Business Overview
  58. 8.10.3 Laboratorio Farmaceutico De Pernambuco Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Laboratorio Farmaceutico De Pernambuco Chagas Disease Treatment Product Portfolio
  60. 8.10.5 Laboratorio Farmaceutico De Pernambuco Recent Developments
  61. 8.11 Maprimed S.A
  62. 8.11.1 Maprimed S.A Company Information
  63. 8.11.2 Maprimed S.A Business Overview
  64. 8.11.3 Maprimed S.A Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Maprimed S.A Chagas Disease Treatment Product Portfolio
  66. 8.11.5 Maprimed S.A Recent Developments
  67. 8.12 Nortec Quimica SA
  68. 8.12.1 Nortec Quimica SA Company Information
  69. 8.12.2 Nortec Quimica SA Business Overview
  70. 8.12.3 Nortec Quimica SA Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Nortec Quimica SA Chagas Disease Treatment Product Portfolio
  72. 8.12.5 Nortec Quimica SA Recent Developments
  73. 8.13 Novartis AG
  74. 8.13.1 Novartis AG Company Information
  75. 8.13.2 Novartis AG Business Overview
  76. 8.13.3 Novartis AG Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Novartis AG Chagas Disease Treatment Product Portfolio
  78. 8.13.5 Novartis AG Recent Developments
  79. 8.14 Oblita Therapeutics BVBA
  80. 8.14.1 Oblita Therapeutics BVBA Company Information
  81. 8.14.2 Oblita Therapeutics BVBA Business Overview
  82. 8.14.3 Oblita Therapeutics BVBA Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Oblita Therapeutics BVBA Chagas Disease Treatment Product Portfolio
  84. 8.14.5 Oblita Therapeutics BVBA Recent Developments
  85. 8.15 Sanofi Aventis
  86. 8.15.1 Sanofi Aventis Company Information
  87. 8.15.2 Sanofi Aventis Business Overview
  88. 8.15.3 Sanofi Aventis Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Sanofi Aventis Chagas Disease Treatment Product Portfolio
  90. 8.15.5 Sanofi Aventis Recent Developments
  91. 8.16 AstraZeneca
  92. 8.16.1 AstraZeneca Company Information
  93. 8.16.2 AstraZeneca Business Overview
  94. 8.16.3 AstraZeneca Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 AstraZeneca Chagas Disease Treatment Product Portfolio
  96. 8.16.5 AstraZeneca Recent Developments
  97. 8.17 Bayer AG
  98. 8.17.1 Bayer AG Company Information
  99. 8.17.2 Bayer AG Business Overview
  100. 8.17.3 Bayer AG Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Bayer AG Chagas Disease Treatment Product Portfolio
  102. 8.17.5 Bayer AG Recent Developments
  103. 8.18 Johnson & Johnson
  104. 8.18.1 Johnson & Johnson Company Information
  105. 8.18.2 Johnson & Johnson Business Overview
  106. 8.18.3 Johnson & Johnson Chagas Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Johnson & Johnson Chagas Disease Treatment Product Portfolio
  108. 8.18.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chagas Disease Treatment Value Chain Analysis
  2. 9.1.1 Chagas Disease Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chagas Disease Treatment Production Mode & Process
  6. 9.2 Chagas Disease Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chagas Disease Treatment Distributors
  9. 9.2.3 Chagas Disease Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst